Author’s response to reviews

Title: Non-Small Cell Lung Cancer with EML4-ALK Translocation in Chinese Male Never-Smokers is Characterized with Early-Onset and Less-Differentiation

Authors:

Yongjun Guo (yongjunguo@hotmail.com)
Jie Ma (majie@medmail.com.cn)
Wenjing Bao (baowi_7@163.com)
Bing Wei (weibing1999@hotmail.com)
Jiuzhou Zhao (Jiuzhou5578@163.com)
Nan Zhang (nzhang012@163.com)
Shuang Fu (fushuangtt@126.com)
Lu Ding (dingludlc@126.com)
Jihong Zhang (zhangjihong2014@126.com)

Version: 4 Date: 8 January 2014

Author's response to reviews: see over
Jan 08, 2014

Dear Editors of BMJ Cancer:

We have revised the manuscript (Manuscript ID: 4124372561153266) according to your instruction. This manuscript was submitted as a research article entitled “Non-Small Cell Lung Cancer with EML4-ALK Translocation in Chinese Male Never-Smokers is Characterized with Early-Onset and Less-Differentiation.”

We were requested for the following changes:

1. Ethics Statement:

Research involving human subjects (including human material or human data) that is reported in the manuscript must have been performed with the approval of an appropriate ethics committee and be in compliance with the Helsinki Declaration (http://www.wma.net/en/30publications/10policies/b3/index.html). A statement to this effect must appear in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. If a study has been granted an exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption).

-We added this sentence: “The study was approved by the Institutional Ethics Committee of Henan Cancer Hospital.”

2. Please remove any patient-identifying information (age and sex) data from the tables.

-We removed these information in table 4 and revised text accordingly.

3. Acknowledgements

By way of a section ‘Acknowledgements’, please acknowledge anyone who contributed towards the article by making substantial contributions to conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, but who does not meet the criteria for authorship. Please also include the source(s) of funding for each author, and for the manuscript preparation. Authors must describe the role of the funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Please also acknowledge anyone who contributed materials essential for the study. If a language editor has made significant revision of the manuscript, we recommend that you acknowledge the editor by name, where possible.

--We added: “This study was supported by Innovation Fund (11C26213104448) from the State Council of China. We thank Hao Yu and Qingxi Yang for their help in statistical analysis”.

As stated above, we respectfully request that our manuscript be considered for publication in the BMJ Cancer. We look forward to your response.

Sincerely,

Zhang Jihong
Hematology laboratory of Hematology malignancy treatment center
Shengjing Hospital of China Medical University
No.39 Huaxiang Road, Tiexi District
Shenyang, Liaoning 100022
China
Email: zhangjihong2014@126.com
Telephone: 024-96615-24811